Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC6029 | BX 471 |
| Potent, selective non-peptide CCR1 antagonist (Ki = 1 nM for human CCR1). Exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4. Inhibits MIP-α/CCL3-induced intracellular Ca2+ mobilization. Orally active; effectively reduces disease severity in a rat model of multiple sclerosis. Decreases renal fibrosis in a mouse model of obstructive nephropathy. | |
| BCC6031 | BMS 753 |
| RARα-selective agonist (Ki = 2 nM). | |
| BCC6032 | N2-Methyl-L-arginine |
| Selective L-arginine uptake inhibitor (Ki = 500 μM). Inhibits uptake of arginine by the lysosomal system c in human fibroblast in vitro. | |
| BCC6036 | AT 56 |
| Orally active inhibitor of lipocalin-type prostaglandin D synthase (L-PGDS) (Ki = 75 μM, IC50 = 95 μM). Inhibits the production of PGD2 from PGH2 in vitro, with no effect on PGE2 or PGF2α production. | |
| BCC6037 | MMK 1 |
| Potent and selective human formyl peptide receptor FPR2 agonist (EC50 values are 1, 2 and > 10 000 nM at mFRP2, hFPR2 and hFPR1 respectively). Induces migration of human monocytes and neutrophils via a chemotactic mechanism and enhances production of proinflammatory cytokines IL-1β and IL-6. Also activates the neutrophil superoxide-generating NADPH-oxidase. | |
| BCC6038 | BAY-X 1005 |
| 5-lipoxygenase activating protein (FLAP) inhibitor. Inhibits the synthesis of leukotrienes B4 and C4 in animal models; inhibits synthesis of leukotriene B4 in A23187-stimulated leukocytes (IC50 values are 0.026, 0.039 and 0.22 μM for rat, mice and human leukocytes respectively). Displays anti-inflammatory activity. Orally active. | |
| BCC6039 | CP 316819 |
| Selective glycogen phosphorylase inhibitor [IC50 values are 0.017 and 0.034 μM against human skeletal muscle glycogen phosphorylase a (huSMGPa) and liver glycogen phosphorylase a (huLGPa) respectively]. Antihyperglycemic agent. | |
| BCC6040 | INH1 |
| Hec1 inhibitor. Binds Hec1, inhibiting its association with Nek2 and kinetochores. Causes arrest of mitosis and inhibits proliferation in breast cancer cell lines (GI50= 10 - 20 μM). | |
